Eli Lilly is a biopharma giant that could still deliver strong growth. Novo Nordisk's growth story isn't over thanks to Ozempic, Wegovy, and a promising pipeline.

INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D.

Lilly (LLY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many...

The market reacted very positively to Eli Lilly's Q2 earnings report. This isn't the first time the stock has seen a significant run-up in a short period.

As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.

Holding a promising future due to recent success in the obesity drug market, Eli Lilly (NYSE:LLY) appears to be bound for continued gains.

The recent sell-off brought biopharma stocks down by a bit. Nothing has changed about their ability to compete.

A volatile week in the stock market ends with the Nasdaq-100 snapping its weekly losing streak, but all other indices closed down in the red. Eli Lilly (LLY) rallied, SuperMicro (SMCI) plummeted, a...

Long-term stocks, or those that are meant to be held for over a year, let investors ignore daily market fluctuations.

Obesity drugmakers like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO were not immune to the broad market sell-off sparked by the June CPI report, but investors looking to get into these names sho...

CNBC's Jim Cramer on Thursday recommended that investors not base portfolio decisions solely off of macro economic trends, like new employment data or interest rates. He discussed pharmaceutical gi...

Eli Lilly ( LLY ) reported strong quarterly results on Thursaday morning, with revenue increasing 36%, driven primarily by the success of Mounjaro, Zepbound, and Verzenio. The company also saw a si...

Stocks for the health care company soared Thursday after beating on the top and bottom line and raising guidance for the rest of the year. Diane King Hall joins Alex Coffey and Jenny Horne to talk ...

Powered by Mounjaro and Zepbound, Lilly announced staggering sales and earnings growth this morning. The weight loss drug business is so good, Lilly also raised its full-year sales forecast by $3 b...